Humane Genomics

Humane Genomics is a biotechnology startup based in New York City that is focused on developing a platform to engineer cancer-killing viruses with unparalleled specificity and efficiency. Their innovative approach utilizes synthetic biology to target liver cancer as their initial indication. Since its inception in 2019, the company has garnered significant attention and support from investors, culminating in a notable Seed Round investment in 14 September 2021. This latest funding was secured from a consortium of prominent investors including TA Ventures, Asymmetry Ventures, and SAV (Scale Asia Ventures). With the backing of these stakeholders, Humane Genomics is well-positioned to advance its groundbreaking work in the biotechnology and healthcare sectors. The company's relentless pursuit of disrupting the field of cancer treatment through cutting-edge technology aligns with the growing demand for innovative solutions in the healthcare industry. As the startup continues to make strides in its research and development efforts, it is poised to make a lasting impact on the fight against cancer.